OncoSec's TAVO(TM) in Combination with KEYTRUDA® Demonstrated 41% Overall Response Rate and 36% Complete Response in a Late-Stage Metastatic Melanoma Study Featured in 'Clinical Cancer Research'
Stock Information for OncoSec Medical Incorporated
Loading
Please wait while we load your information from QuoteMedia.